Home » Stocks » GOVX

GeoVax Labs, Inc. (GOVX)

Stock Price: $5.95 USD -0.35 (-5.56%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $5.97 +0.02 (0.34%) May 7, 7:58 PM
Market Cap 36.64M
Revenue (ttm) 1.22M
Net Income (ttm) -3.93M
Shares Out 5.33M
EPS (ttm) -2.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $5.95
Previous Close $6.30
Change ($) -0.35
Change (%) -5.56%
Day's Open 5.81
Day's Range 5.56 - 6.09
Day's Volume 516,443
52-Week Range 2.56 - 8.71

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Conference call to be held Thursday, May 6, at 4:30 p.m. Eastern Time

1 week ago - GlobeNewsWire

Therapeutic Vaccine Would Address Medical Need of Over 250 Million Worldwide

1 month ago - GlobeNewsWire

COVID-19 Vaccine Designed as Single-Dose Against Multiple Strains

1 month ago - GlobeNewsWire

Conference call to be held Wednesday, March 24, at 8:00 a.m. Eastern Time

1 month ago - GlobeNewsWire

GeoVax Chairman & CEO David Dodd to Present Corporate Overview

1 month ago - GlobeNewsWire

Filings Made in Corporate Focus Areas of SARS-CoV-2 and Immuno-Oncology

2 months ago - GlobeNewsWire

Virtual Conference to be Held March 9-10, 2021

2 months ago - GlobeNewsWire

Atlanta, GA, Feb. 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines a...

2 months ago - GlobeNewsWire

ATLANTA, GA, Feb. 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines aga...

2 months ago - GlobeNewsWire

GeoVax (NASDAQ: GOVX) shares are trading sharply higher on Monday after the company announced it was awarded an NIH grant to advance its COVID-19 vaccine development. GeoVax is a U.S.-based clinical-sta...

3 months ago - Benzinga

Company Focused on Single-dose Vaccine Against Multiple COVID Strains

3 months ago - GlobeNewsWire

GeoVax Also Participating in BIO@JPM During “J.P. Morgan Week 2021”

4 months ago - GlobeNewsWire

GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q4 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

GeoVax Labs, Inc.'s (GOVX) CEO David Dodd on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Public Offering Completed in September 2020 Provides Resources to Accelerate COVID-19 Vaccine and Immuno-Oncology Programs

6 months ago - GlobeNewsWire

Conference call to be held Friday, November 6, at 8:15 a.m. Eastern Time

6 months ago - GlobeNewsWire

ATLANTA, GA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vac...

6 months ago - GlobeNewsWire

GeoVax Labs (GOVX) news for Monday includes a deal with the National Institutes of Health to develop a vaccine for the novel coronavirus. The post GeoVax Labs News: GOVX Stock Flies 18% on NIH COVID-19 ...

6 months ago - InvestorPlace

Shares of GeoVax Labs Inc. were up 12.8% in trading on Monday after the company announced a patent and material licensing deal with the National Institutes of Health for COVID-19 vaccine development. As...

6 months ago - Market Watch

ATLANTA, GA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vacc...

6 months ago - GlobeNewsWire

ATLANTA, GA, Sept. 29, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and...

7 months ago - GlobeNewsWire

ATLANTA, GA, Sept. 24, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies an...

7 months ago - GlobeNewsWire

About GOVX

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and... [Read more...]

Industry
Biotechnology
Founded
2001
CEO
David Dodd
Employees
7
Stock Exchange
NASDAQ
Ticker Symbol
GOVX
Full Company Profile

Financial Performance

In 2020, GeoVax Labs's revenue was $1.82 million, an increase of 55.09% compared to the previous year's $1.18 million. Losses were -$2.96 million, 24.8% more than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for GeoVax Labs stock is "Buy" and the 12-month stock price forecast is 8.00.

Price Target
$8.00
Analyst Consensus: Buy